G

Genedrive PLC
LSE:GDR

Watchlist Manager
Genedrive PLC
LSE:GDR
Watchlist
Price: 2.4 GBX -2.04% Market Closed
Market Cap: 13m GBX
Have any thoughts about
Genedrive PLC?
Write Note

Genedrive PLC
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genedrive PLC
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
G
Genedrive PLC
LSE:GDR
Capital Expenditures
-ÂŁ36k
CAGR 3-Years
29%
CAGR 5-Years
15%
CAGR 10-Years
32%
Oxford Nanopore Technologies PLC
LSE:ONT
Capital Expenditures
-ÂŁ27.3m
CAGR 3-Years
-1%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Capital Expenditures
-ÂŁ4.9m
CAGR 3-Years
8%
CAGR 5-Years
-34%
CAGR 10-Years
N/A
Ergomed PLC
LSE:ERGO
Capital Expenditures
-ÂŁ2.5m
CAGR 3-Years
-37%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Capital Expenditures
-ÂŁ20k
CAGR 3-Years
-26%
CAGR 5-Years
17%
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Capital Expenditures
-ÂŁ6.7m
CAGR 3-Years
-69%
CAGR 5-Years
-178%
CAGR 10-Years
-67%
No Stocks Found

Genedrive PLC
Glance View

Market Cap
13m GBX
Industry
Life Sciences Tools & Services

Genedrive Plc is a holding company, which engages in the development of drugs and disease diagnostics. The Company’s Genedrive device is a molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company’s commercial products include Genedrive MT-RNR1, Genedrive BioPlex, Genedrive HCV ID Kit and Genedrive 96 SARS-CoV-2 Ki. Genedrive MT-RNR1 is a commercial test for antibiotic induced hearing loss. Genedrive BioPlex is developed for the determination of military biothreats from pathogens. Genedrive HCV ID Kit is effective in the diagnosis of Hepatitis C Virus (HCV) infection in resource limited settings. Genedrive 96 SARS-CoV-2 Ki is a plate format of a COVID-19 molecular test for high throughput use, which detects all known variants of COVID-19.

GDR Intrinsic Value
0.41 GBX
Overvaluation 83%
Intrinsic Value
Price
G

See Also

What is Genedrive PLC's Capital Expenditures?
Capital Expenditures
-36k GBP

Based on the financial report for Dec 31, 2023, Genedrive PLC's Capital Expenditures amounts to -36k GBP.

What is Genedrive PLC's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
32%

Over the last year, the Capital Expenditures growth was 51%. The average annual Capital Expenditures growth rates for Genedrive PLC have been 29% over the past three years , 15% over the past five years , and 32% over the past ten years .

Back to Top